Eli Lilly and Company $LLY Stock Sold by Bank & Trust Co

Bank & Trust Co lessened its holdings in Eli Lilly and Company (NYSE:LLY) by 8.6% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 10,054 shares of the company’s stock after selling 947 shares during the quarter. Eli Lilly and Company makes up about 5.8% of Bank & Trust Co’s holdings, making the stock its 3rd largest position. Bank & Trust Co’s holdings in Eli Lilly and Company were worth $11,633,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the business. S.E.E.D. Planning Group LLC acquired a new position in shares of Eli Lilly and Company during the 3rd quarter worth about $252,000. Benedict Financial Advisors Inc. raised its position in shares of Eli Lilly and Company by 67.0% during the 3rd quarter. Benedict Financial Advisors Inc. now owns 304 shares of the company’s stock worth $352,000 after acquiring an additional 122 shares in the last quarter. MRA Advisory Group lifted its stake in Eli Lilly and Company by 194.2% during the third quarter. MRA Advisory Group now owns 859 shares of the company’s stock worth $994,000 after purchasing an additional 567 shares during the last quarter. Lake Hills Wealth Management LLC purchased a new stake in Eli Lilly and Company during the third quarter worth approximately $1,058,000. Finally, Worth Asset Management LLC boosted its holdings in Eli Lilly and Company by 9.4% in the third quarter. Worth Asset Management LLC now owns 1,786 shares of the company’s stock valued at $2,067,000 after purchasing an additional 153 shares in the last quarter. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In related news, EVP Patrik Jonsson sold 6,500 shares of the business’s stock in a transaction dated Monday, August 17th. The stock was sold at an average price of $1,175.10, for a total value of $7,638,150.00. Following the transaction, the executive vice president owned 54,147 shares in the company, valued at $63,628,139.70. The trade was a 10.72% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Anat Hakim sold 5,000 shares of the company’s stock in a transaction that occurred on Friday, August 7th. The shares were sold at an average price of $1,190.00, for a total value of $5,950,000.00. Following the sale, the executive vice president directly owned 11,875 shares of the company’s stock, valued at approximately $14,131,250. This represents a 29.63% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 13,500 shares of company stock valued at $15,958,170. Insiders own 0.14% of the company’s stock.

Eli Lilly and Company Stock Performance

Shares of LLY stock traded up $39.89 during trading hours on Wednesday, hitting $1,197.38. The stock had a trading volume of 1,165,722 shares, compared to its average volume of 2,967,986. The company has a debt-to-equity ratio of 1.41, a current ratio of 1.35 and a quick ratio of 1.00. The firm has a market capitalization of $1.13 trillion, a PE ratio of 40.19, a PEG ratio of 1.40 and a beta of 0.46. The stock’s 50 day moving average is $1,173.98 and its 200 day moving average is $1,092.69. Eli Lilly and Company has a twelve month low of $783.85 and a twelve month high of $1,292.65.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Wednesday, August 5th. The company reported $8.38 EPS for the quarter, beating the consensus estimate of $6.40 by $1.98. Eli Lilly and Company had a net margin of 33.53% and a return on equity of 97.83%. The firm had revenue of $22.97 billion during the quarter, compared to the consensus estimate of $20.82 billion. During the same quarter in the prior year, the firm earned $6.31 EPS. Eli Lilly and Company’s revenue for the quarter was up 47.7% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. As a group, research analysts forecast that Eli Lilly and Company will post 36.66 earnings per share for the current fiscal year.

Eli Lilly and Company News Roundup

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Strong GLP-1 growth outlook: Analysts remain constructive on Lilly’s Mounjaro and Zepbound franchises, while anticipated momentum from the oral GLP-1 candidate Foundayo could support growth in the second half of 2026. Recent data presented at a diabetes meeting showed Foundayo produced greater weight loss and better blood-sugar control than oral semaglutide in adults with type 2 diabetes, although commercial and regulatory execution remain important. Eli Lilly’s Breakout May Occur Soon – H2’26 Foundayo Tailwinds
• Positive Sentiment: Pipeline diversification: Lilly is working to reduce reliance on obesity and diabetes products through oncology, immunology, neuroscience, and other areas. The FDA granted orphan-drug designation to experimental cancer treatment olomorasib, providing potential development incentives and exclusivity benefits. Lilly also expanded its drug-discovery collaboration with Gate Bioscience in a deal potentially worth more than $870 million. Eli Lilly Stock Gains on Regulatory Win
• Positive Sentiment: Additional development progress: Early-stage updates for elt­re­kibart and a new basal-insulin candidate point to continued investment in Lilly’s pipeline. Its partnership with insitro is also making machine-learning tools available through Lilly TuneLab, potentially improving external drug discovery and future licensing opportunities. Lilly’s New Basal Insulin Candidate Clears Key Early Trial Milestone
• Neutral Sentiment: Upcoming earnings focus: Investor attention is building ahead of third-quarter results. Recent coverage points to improving operating momentum, but expectations are already high following the company’s prior revenue and earnings outperformance.
• Negative Sentiment: Valuation and concentration risks: Commentary warns that Lilly trades at a substantial premium to the broader market, leaving limited room for disappointing sales, pricing, or guidance. Falling U.S. prices for Zepbound and Mounjaro could also pressure future margins or growth assumptions. Eli Lilly: Impressive Growth, Questionable Valuation
• Negative Sentiment: Childhood-obesity guidance: New World Health Organization guidelines discourage certain approaches to treating childhood and adolescent obesity, creating potential uncertainty around how quickly GLP-1 therapies could expand in younger populations. WHO Childhood Obesity Guidelines

Analysts Set New Price Targets

Several equities analysts have commented on the stock. HSBC increased their price target on shares of Eli Lilly and Company from $850.00 to $940.00 and gave the company a “reduce” rating in a research note on Thursday, September 10th. Leerink Partners upped their target price on shares of Eli Lilly and Company from $1,119.00 to $1,232.00 and gave the company an “outperform” rating in a report on Thursday, June 25th. Bank of America increased their target price on shares of Eli Lilly and Company from $1,251.00 to $1,334.00 and gave the company a “buy” rating in a research report on Friday, July 10th. The Goldman Sachs Group lifted their price target on shares of Eli Lilly and Company from $1,367.00 to $1,371.00 and gave the stock a “buy” rating in a research note on Thursday, September 17th. Finally, Morgan Stanley boosted their price target on shares of Eli Lilly and Company from $1,419.00 to $1,430.00 and gave the company an “overweight” rating in a research report on Wednesday. One investment analyst has rated the stock with a Strong Buy rating, twenty-five have given a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Eli Lilly and Company has an average rating of “Moderate Buy” and an average price target of $1,312.36.

About Eli Lilly and Company

Eli Lilly and Company is a global pharmaceutical company headquartered in Indianapolis, Indiana. Founded in 1876 by Colonel Eli Lilly, the company researches, develops, manufactures and markets medicines for a range of conditions, including diabetes, obesity, cancer, immunological disorders, neurological diseases and pain.

Its products include Mounjaro and Zepbound, which contain tirzepatide and are used for type 2 diabetes and chronic weight management, respectively. Other key medicines include Trulicity for diabetes, Verzenio for certain breast cancers, Taltz for inflammatory and autoimmune conditions, Humalog insulin, and Kisunla for early symptomatic Alzheimer’s disease.